Healthcare Industry News: sinusitis
News Release - September 27, 2010
Acclarent, Inc. Introduces Two New Innovations for Minimally-Invasive Sinus Surgery during AAO - Head and Neck Surgery ConferenceNew tools build upon company's minimally-invasive Balloon Sinuplasty Platform to improve visualization capabilities during sinus surgery for the treatment of chronic rhinosinusitis.
BOSTON, Sept. 27 -- (Healthcare Sales & Marketing Network) -- Acclarent, Inc., a leader in minimally-invasive sinus surgery, today announced the introduction of two new technologies designed to improve visualization during sinus surgery -- The Acclarent Cyclops™ Multi-Angle Endoscope and the Relieva Luma Sentry™ Sinus Illumination System. The Relieva Luma Sentry™ Sinus Illumination System builds upon Acclarent's 510k cleared Relieva Luma® Technology. The Acclarent Cyclops™ Multi-Angle Endoscope is CE Marked and currently pending 510k clearance. These products, which are the latest additions to the company's minimally-invasive Balloon Sinuplasty™ Technology Platform, will be featured at the Annual Meeting of the American Academy of Otolaryngology -- Head and Neck Surgery, September 26-29 in Boston.
The Acclarent Cyclops™ Multi-Angle Endoscope offers an unlimited field of vision to examine every angle with one scope. The Acclarent Cyclops™ Multi-Angle Endoscope's precise engineering and optically-ground, hand-polished sapphire lens enable the surgeon to pan up to 90-degrees and freely rotate the field of view. This allows the surgeon to directly visualize the natural opening of the sinuses, even the maxillary.
The Relieva Luma Sentry™ Sinus Illumination System safely navigates tortuous sinus anatomy and easily confirms sinus access. The Relieva Luma Sentry™ Sinus Illumination System also enables ENT surgeons to efficiently exchange instruments without losing sinus access. Relieva Luma Sentry™ Sinus Illumination System is the next generation in transcutaneous illumination providing surgeons with confident direct visual confirmation of sinus access with maximum control.
About the Balloon Sinuplasty™ System:
Since 2005, more than 120,000 patients have been treated with Balloon Sinuplasty™ Technology in operating rooms and office settings. Acclarent's comprehensive visualization capabilities enable surgeons to confidently access, dilate and irrigate targeted sinuses throughout every aspect of Endoscopic Sinus Surgery (ESS) with Balloon Sinuplasty™ Technology, and provide their patients with minimally invasive options that have been repeatedly proven safe and effective worldwide.
For additional information, please visit www.Acclarent.com or contact your local Acclarent ENT Consultant.
Acclarent is a global medical technology company dedicated to the development of innovative products to further meet the needs of ENT surgeons and their patients. Based in Menlo Park, Calif., the company operates as a business unit of Ethicon, Inc., a Johnson & Johnson company. Through its core technologies and commitment to innovation, Acclarent will continue to advance novel technologies in all areas of ENT. Acclarent markets and sells its products worldwide and its technology has been used by thousands of physicians. For more information about Acclarent, visit www.Acclarent.com.
©2010 Acclarent, Inc. All rights reserved.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.